12results about "Fluorine compound active ingredients" patented technology

This disclosure relates to targeting moieties, such as peptides and antibodies, that can bind to DLL3. The disclosure also provides targeted constructs, which may include a targeting moiety conjugated to a chelating agent for cargo association via an optional linker. Methods for constructing the constructs and formulations thereof are also provided. Methods for using the constructs and / or formulations to treat a target, for example, to treat or prevent cancer, are also described.

Provided is compositions and methods for treating dental caries in individuals and animals. The compositions may be zinc compositions of [Zn(NH3)4]F2. Also provided are methods of making inorganic zinc compounds (e.g., ZnO, Zn(OH)2, or Zn(OH)F) onto the surface of a carious lesion. The deposition of inorganic zinc compound (e.g., ZnO, Zn(OH)2, or Zn(OH)F) may occur from dilution of a Zn2+ / NH3 solution (e.g., an aqueous or alcohol-based solution) into water (e.g., deionized water). The formation of inorganic zinc compound (e.g., ZnO, Zn(OH)2, or Zn(OH)F) may be instantaneous upon dilution.

A dental composition is described that includes a homogeneous solution having a zinc complex stabilized with an amine-containing ligand and a fluoride anion source. A method for treating or preventing caries activity on a tooth surface using the dental composition is also described, as are kits.

This disclosure relates to targeting moieties, such as peptides and antibodies, that can bind to DLL3. The disclosure also provides targeted constructs that may include a targeting moiety conjugated to a chelating agent for cargo association via an optional linker. Methods for constructing the constructs and formulations thereof are also provided. Methods for using the constructs and / or formulations to treat a target, for example, to treat or prevent cancer, are also described.

The present invention relates to improved phosphopeptide stabilized amorphous calcium phosphate and / or amorphous calcium fluoride phosphate complexes and compositions containing these complexes. Methods of making the complexes of the invention and treating or preventing oral conditions are also provided. In one aspect, the invention provides a method for treating or preventing halitosis in an individual in need thereof, the method comprising administering to the oral cavity of the individual a stabilized amorphous calcium phosphate (ACP) and / or a stabilized amorphous calcium fluoride phosphate (ACFP), thereby treating or preventing halitosis. In another aspect, the invention provides a zinc-associated stabilized amorphous calcium phosphate (ACP) and / or a zinc-associated stabilized amorphous calcium fluoride phosphate (ACFP) complex.

The present invention relates to the field of dental care products used for dental diseases, periodontal diseases and or any other oral disorders, or for cosmetic therapies. It provides an oral film (5), in particular a pharmaceutical oral film, that can be used for simultaneous therapy of a gum and teeth of a subject, e.g., for therapy and / or prevention of periodontal and dental diseases or disorders, or for cosmetic therapies such as for tooth whitening. The invention also provides a method, e.g., a cosmetic method using said film and a method for preparing said oral film (5).

Embodiments of the invention disclosed herein provide methods for using certain18F-based PET tracers in selected imaging techniques including studies of T cell localization and function that is associated with systemic immunity. Embodiments of the invention include methods that use multiple PET tracers selected for their ability to observe certain regions in the subject in which the tracers accumulate and then determining a ratio of the signal intensity observed in the region with the first tracer with the signal intensity observed in the region in second tracer as a way to characterize systemic immunity. The methods disclosed herein that allow the quantification of T cell function in relation to tumor burden are useful in patient selection and therapy guidance, both of which are expected to dramatically increase success of immunotherapies and improve patients' clinical outcome.

To provide: a pharmaceutical dialysate for maintaining physiological levels of thiosulfate ions in a subject undergoing hemodialysis; and a method of producing the pharmaceutical dialysis solution.SOLUTION: A thiosulfate ion-spiked pharmaceutical dialysate comprises sodium thiosulfate, water, an acid concentrate solution, and a bicarbonate concentrate solution, wherein the thiosulfate ion-spiked pharmaceutical dialysate has a pH greater than about 7.0, wherein a concentration of thiosulfate ions in the thiosulfate ion-spiked pharmaceutical dialysate is 100 micromolar or less, and wherein the thiosulfate ion-spiked pharmaceutical dialysate is used to be administered to the subject together with one or more of copper, fluoride ions, iodine, iron, manganese, magnesium, nitrite ions, phosphorus, selenium, and zinc.SELECTED DRAWING: Figure 1

The present invention relates to compositions containing keratin, methods for producing such compositions, and various therapeutic applications thereof, particularly in dentistry and bone restoration. In particular, the present invention relates to keratin compositions produced by dissolving keratin in a solvent, casting the resulting solution, and drying it.

An oral care fluoride treatment composition comprising 0.1 wt-% to 3.0 wt-% of a crosslinked poly acid having carboxylic acid side groups; a pharmaceutically acceptable buffer; at least 1.0 wt-% of sodium fluoride; and 0.025 wt-% to 1.75 wt-% of a multivalent cation salt, wherein the multivalent cation salt comprises a chloride salt, a nitrate salt, a gluconate salt, a lactate salt, an acetate salt, a sulfate, hydrates thereof, and combinations thereof; one or more fluorine-containing compounds selected from sodium monofluorophosphate, stannous fluoride, calcium fluoride, strontium fluoride, zinc fluoride, zinc potassium fluoride, ammonium fluoride, potassium fluoride, magnesium fluoride, and combinations thereof; and at least 60 wt-% water; wherein the weight percentages are based on the total weight of the composition.